COVID-19 rapid guideline: managing COVID-19 (NG191)Product type:GuidanceProgramme:NICE guidelineLast updated: 1 May 2025Published: 23 March 2021
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 May 2025Published: 29 March 2023
Molnupiravir for treating COVID-19 (TA1056)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 April 2025
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 May 2024
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)Product type:GuidanceProgramme:NICE guidelineLast updated: 25 January 2024Published: 18 December 2020
COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)Product type:GuidanceProgramme:NICE guidelineLast updated: 28 September 2023Published: 1 April 2020
Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023